The biochip assay market is a large and expanding space with exciting potential new applications in drug discovery, drug testing, point of care diagnostics and cell flow assay tests.  At present, current interrogation of the biochip cell assays utilises fluorescently tagged markers which are trapped on the biochip surface and characterised semi-quantitatively using manual counting techniques. 

A truly quantitative analysis of the cell assays is important for progress in the thrombosis, arthrosclerosis' and cardiovascular market space.  The aim of the study is to define applications and technical feasibility of electrochemical sensors being developed at third level institutions and the subsequent intergration with Cellix  biochips in monitoring of cardiovascular and anti-inflammatory drugs.  This study will involve the identification of suitable electrochemical senors and clearly identify future potential via market research. 

Current cell counting assays are based on chemical, fluorescence and other optical techniques.  The VenaEC biochiop is pre-treated with collagen, fibrinogen, VCAM, ICAM or selectins as an ahdesion surgace for targets cells such as platelets, leukocytes and monocytes.  Pre-incubation of the cells with a fluorescent tag marker enables manual counting of the cells adhered into the surface of the microfluidic channel.  Future cell counting diagnostic devices will require more accurate quantitative measurement of the cells adhered to the microfluidic channel and electrochemical detection is an optimal method for detection. 

 

Inflammation: Leukocyte ahdesion to VCAM, ICAM and selectin preparted microfluidic channels on biochips for application  in monitoring of artherosclerosis, monocyte adhesion/plaque formations.